Mainstay Set To Launch ReActiv8 Neurostimulator In Germany

Mainstay Medical is ready to launch its ReActiv8 neurostimulator, starting in Germany, now that the implantable device has a CE mark for the treatment of chronic back pain, the company announced May 25.

Mainstay Medical is ready to launch its ReActiv8 neurostimulator, starting in Germany, now that the implantable device has a CE mark for the treatment of chronic back pain, the company announced May 25.

Mainstay has its own direct sales force that will focus on German hospitals that treat a large back-pain patient population...

More from Archive

More from Medtech Insight